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Background: A critical and as-yet unmet need in Alzheimer disease (AD) research is the development of novel
markers that can identify individuals at risk for cognitive decline due to AD. This would aid intervention trials
designed to slow the progression of AD by increasing diagnostic certainty, and provide new pathophysiologic clues
and potential drug targets.
Results: We used two metabolomics platforms (gas chromatography-time of flight mass spectrometry [GC-TOF]
and liquid chromatography LC-ECA array [LC-ECA]) to measure a number of metabolites in cerebrospinal fluid (CSF)
from patients with AD dementia and from cognitively normal controls. We used stepwise logistic regression models
with cross-validation to assess the ability of metabolite markers to discriminate between clinically diagnosed AD
participants and cognitively normal controls and we compared these data with traditional CSF Luminex
immunoassay amyloid-β and tau biomarkers. Aβ and tau biomarkers had high accuracy to discriminate cases and
controls (testing area under the curve: 0.92). The accuracy of GC-TOF metabolites and LC-ECA metabolites by
themselves to discriminate clinical AD participants from controls was high (testing area under the curve: 0.70 and
0.96, respectively).
Conclusions: Our study identified several CSF small-molecule metabolites that discriminated especially well
between clinically diagnosed AD and control groups. They appear to be suitable for further confirmatory and
validation studies, and show the potential to provide predictive performance for AD.
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Alzheimer’s disease (AD) is a major public health threat
and there is an urgent need to validate biomarkers that
are relevant to early detection and disease progression
[1-9]. In the early clinical and "preclinical" stages of the
illness, the symptoms of forgetfulness can be ambiguous* Correspondence: kaddu001@mc.duke.edu
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distribution, and reproduction in any mediumand easily confused with the benign forms of memory
loss that are associated with normal aging. A recent
clinico-pathologic comparison study of more than 900
patients diagnosed at major centers in the United States
found that 17-30% of clinical diagnoses were inconsist-
ent with autopsy diagnoses [1]. There is a critical but
unmet need for early detection and intervention of AD,
as well as for identifying disease-modifying therapies
that will slow the progression of dementia, delay the on-
set of dementia or prevent AD [2,4,6-9]. There is a need
for objectively and precisely measurable biomarkers toCentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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tive and psychometric tests [3,5,8,9]. If they are devel-
oped, validated signatures for AD will enable a rapid
identification of prodromal AD patients and could po-
tentially enable the evaluation of drug responses, accel-
erating the whole process of drug development [2-4,6-8].
The development of AD biomarkers is complicated by
the lack of diagnostic precision, difficulty in obtaining
post-mortem verification, variability in clinical features
and rates of progression, complex disease genetics and
the multiple molecular pathways affected. Different types
of biomarkers have been pursued for the detection of
AD using imaging, genetic and biochemical tools
[3,5,8-11]. Studies of blood markers have had difficulty
capturing neurochemical changes consistently [9]. While
dozens of cerebrospinal fluid (CSF) studies have been
conducted in AD participants, such studies have usually
either used a small sample size or examined only a few
biochemical metabolites at a time due to logistic difficul-
ties. The multicenter Alzheimer's Disease Neuroimaging
Initiative study has enabled investigators to establish the
utility of CSF Abeta and tau markers for discriminating
AD from controls [5]. Neuroimaging methods (e.g.,
volumetric magnetic resonance imaging, amyloid posi-
tron emission tomography [PET] scans) offer promise as
surrogate markers of neuronal loss and neuropathology,
and the florbetapir F18 PET scan—for the detection of
neuritic beta-amyloid plaques—just became available
clinically as a diagnostic adjunct [8,10,11]. However,
Abeta plaque is not specific for AD since it is also
present in dementia with Lewy bodies, advanced
Parkinson's disease and up to one-third of cases of nor-
mal aging [10,11]. There has been a lack of validated
“mega” metabolic platforms that can simultaneously
study the dozens of different biochemical pathways that
may be affected in AD, both in relation to each other
and in relation to clinical characteristics of the disease.
Such platforms could potentially provide new insights,
adding to those of single biomarker studies.
Metabolomics, the omics science of biochemistry, is a
global approach to understanding the regulation of
metabolic pathways and the metabolic networks of a
biological system [12-23]. Metabolomics complements
data derived from genomics, transcriptomics and proteo-
mics to assist in providing a systems approach to the
study of human health and disease. Metabolomics is the
comprehensive study of the metabolome, the repertoire
of bio-chemicals (or small molecules) present in cells,
tissue and/or body fluids. The metabolome defines a
metabolic state as regulated by net interactions between
genetic and environmental influences, and provides in-
formation that can possibly bridge the gap between
genotype and phenotype. Metabolomics provides power-
ful tools to map perturbations in biochemical pathwaysand networks in disease and in response to treatment
[15,16]. For example, we have identified major changes
in the norepinephrine pathway in patients with AD [24]
and also changes in the ceramide-sphingomyelin path-
way [25]. We have mapped several pathways implicated
in schizophrenia and in response to antipsychotics
[26-30]. In depression, we have identified changes in
neurotransmitter pathways, lipid metabolism and beta-
oxidation among other changes [31-33], and we were
able to demonstrate that a patient’s metabolic profile
(metabotype) enables the prediction of response to the
antidepressant sertraline [34].
Recently, we applied metabolomics approaches to pro-
file CSF derived from a cohort of clinically diagnosed
AD patients and cognitively normal controls to map glo-
bal biochemical changes in AD. We have employed a li-
quid chromatography LC-ECA array (LC-ECA)
metabolomics platform to identify metabolites within
key neurotransmitter pathways of tryptophan, tyrosine
and purine that are implicated in the pathogenesis of
AD [35]. This platform has been extremely useful for the
study of central nervous system diseases and their treat-
ment [25,29,30,36-38]. Since different profiling method-
ologies have distinct advantages for conducting
metabolomic studies and cover different areas of bio-
chemistry, in this paper we incorporate an additional
platform for our analyses: the gas chromatography-time
of flight (GC-TOF) mass spectrometry. GC-TOF enables
the interrogation of over 160 metabolites of intermediary
metabolism and provides an overview of metabolic
changes. We build classification models for the disease
phenotype with different combination of metabolomics
and pathogenesis variables to derive initial estimates of




Metabolomic, protein and genetic data for the current
study were gathered from a cross-section of participants
who were recruited and evaluated in clinical research by
the Penn Memory Center [10]. Most of these partici-
pants were enrolled in a prospective multi-site longitu-
dinal biomarker study and were also included in our
prior report focusing on LC-ECA metabolites [35]. Forty
AD patients and 38 controls with banked CSF samples
were analyzed for this report. Written informed consent
was collected as appropriate, and all protocols were ap-
proved by the University of Pennsylvania and the Duke
University Medical Center institutional review boards.
Inclusion and exclusion criteria
For the AD subgroup, subjects had to meet National In-
stitute of Neurological, Communicative Disorders and
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ciation criteria for probable or possible AD; all but one
patient were classified as having mild to moderate de-
mentia based on combination of clinical judgment, Mini
Mental State Exam (MMSE) [39] score and Functional
Rating Scale (FRS) [40] score. Participants could be on
stable approved therapies. Participants were excluded
from this group if they had a history of clinically mean-
ingful stroke, Parkinson's disease, untreated current
major depression, psychosis or a primary diagnosis of a
non-AD dementia.
To be included in the cognitively normal subgroup,
the following inclusion criteria had to be met: 1) No sig-
nificant cognitive impairment verified by psychometric
testing norms, and 2) No significant change in functional
abilities verified by a knowledgeable informant. Partici-
pants were excluded if they had a history of significant
stroke, current untreated major depression, psychosis,
mild cognitive impairment (MCI) or dementia. Subjects
in both groups had to be over 65, have a reliable inform-
ant and consent to longitudinal follow up.
Diagnostic assessments were generally made in a con-
sensus conference after comprehensive neurologic, phys-
ical and neuropsychological testing was performed. Most
patients had multiple psychometric tests, including the
Clinical Dementia Rating, the Dementia Rating Scale-
Second Edition (DRS-2), the MMSE, and tests of frontal
executive function, memory, language, praxis, visuo-
spatial construction, motor performance, mood and
function. MMSE scores were not always available at the
time of baseline blood collection but the nearest avail-
able MMSE was used for staging purposes along with
function and clinical judgment.
CSF collection
Baseline CSF samples obtained in polypropylene tubes
were utilized for metabolomics. CSF was obtained, as
described previously [5], by lumbar puncture using
an atraumatic Sprotte needle in most cases. To minimize
contamination from blood associated with needle
insertion, the first 1-2 ml of CSF (or more if needed)
were discarded and the next 20 ml were aliquoted into
0.5 ml portions, bar coded and stored in a -80°C freezer
until processing. The standardized Luminex multiplex
assay technique for amyloid beta 1-42 (Ab42), total tau
(t-tau) and tau phosphorylated at the threonine 181
position (p-tau) are described elsewhere [5]. Aliquots
were shipped overnight on dry ice for metabolomics
processing.
Metabolomics profiling: LC-ECA
The LC-ECA platform that has been extensively used
and validated in our prior studies in neurodegenerative
and psychiatric disorders [17,34,41-43]. The method isspecific for compounds that will undergo LC-ECA oxi-
dation or reduction, and includes multiple compounds
from the tyrosine, tryptophan, sulfur amino acid and
purine pathways, as well as markers of oxidative stress
and protection (see Additional file 1: Table S1). At the
time of preparation, a pool was created from equal
amounts of small aliquots of each study sample, which
was treated identically to a sample. The pooled samples
were run after every six study samples, followed by a
known standards mix to ensure uniformity along the
length of the run. Metabolite peak identification was car-
ried out using the CEAS software (ESA, Inc., Chelms-
ford, MA). The main metabolite peaks of knowns and
unknowns were aligned and relative concentrations to a
central CSF sample pool (taken at 100%) were measured.
These peak-tables were used for the subsequent statis-
tical analysis where we focused on 71 total metabolites,
of which 24 were known compounds (Additional file 1:
Table S1).
GC-TOF mass spectrometry
CSF samples were aliquoted and maintained at -80°C
until use, at which point 30 μl of CSF samples were
thawed, extracted and derivatized. Briefly, 15 μl aliquots
were extracted with 1 ml of degassed acetonitrile:isopro-
panol:water (3:3:2) at -20°C, centrifuged and decanted
with subsequent evaporation of the solvent to complete
dryness. A clean-up step with acetonitrile/water (1:1) re-
moved membrane lipids and triglycerides, and the super-
natant was again dried down. Internal standards C8-C30
fatty acid methyl esters were added and the sample was
derivatized with methoxyamine hydrochloride in pyri-
dine and subsequently by N-Methyl-N-(trimethylsilyl)
trifluoroacetamide (MSTFA) (Sigma-Aldrich) for
trimethylsilylation of acidic protons.
A Gerstel MPS2 automatic liner exchange system was
used to inject 1 μl of sample at 50°C (ramped to 250°C)
in splitless mode with a 25-second splitless time. An
Agilent 6890 gas chromatograph (Santa Clara, CA) was
used with a 30 m long, 0.25 mm i.d. Rtx5Sil-MS column
with 0.25 μm 5% diphenyl film; an additional 10 m inte-
grated guard column was used (Restek, Bellefonte PA).
Chromatography was performed at a constant flow of
1 ml/minute, ramping the oven temperature from 50°C
for to 330°C over 22 minutes. Mass spectrometry used a
Leco Pegasus IV time of flight mass spectrometer with a
280°C transfer line temperature, electron ionization at -
70 V and an ion source temperature of 250°C. Mass
spectra were acquired from m/z 85-500 at 20 spectra/
second and 1750 V detector voltage. Result files were
exported to our servers and further processed by our
metabolomics BinBase database. All database entries in
BinBase were matched against the Fiaehn mass spectral
library of 1,200 authentic metabolite spectra using
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NIST05 commercial library. Identified metabolites were
reported if present with at least 50% of the samples per
study design group (as defined in the SetupX database
[44]). Quantitative data were normalized to the sum in-
tensities of all known metabolites and used for statistical
investigation. Data on a total of 299 metabolites were
collected using the MS platform.
Statistical methods
Statistical analysis was performed in two stages to find
variables that discriminate between AD participants and
controls. First, univariate analyses were performed to
understand the potential associations between the covar-
iates collected and the disease. Importantly, we investi-
gated the use of AD treatment drugs (cholinesterase
inhibitors and memantine), as well as antidepressants,
antipsychotics, anxiolytics, corticosteroids and statins to
identify metabolites that might potentially be associated
with drug metabolism and/or response. Second, multi-
variate modeling was performed using different combi-
nations of data types (metabolomic, proteins, etc.) to
evaluate the potential discriminatory power of each of
these data types alone and in combination for predicting
AD. To evaluate the predictive potential of these vari-
ables, the models were evaluated using cross-validation
to assess the predictive performance of the models and
further refine the variable included in a prediction ana-
lysis, so that the resulting models were evaluated on the
testing data, as opposed to the training data.
Univariate analysis
Fisher’s exact tests were performed to examine the poten-
tial association of gender, race, and the use of different
classes of drugs with disease status; two-sample t tests
were used to test the difference in education, age and
MMSE score between the two diagnostic groups.
Model building to evaluate the discrimination potential of
variables
To evaluate the discriminatory power of the metabolites
and compare to the Luminex values, we built predictive
models of AD vs. control status. Prior to model-building
analysis, the raw metabolite values were visually
inspected by quantile-quantile normal plots to assess
normality. Metabolites were log-transformed to improve
normality. Metabolites were also filtered to prevent any
potential confounding with the drug therapies used to
treat the disease. This was done because different drugs
are used in AD participants than in controls, and it is
expected that metabolite profiles could change in re-
sponse to treatment. Then, for the nominally signifi-
cantly associated drugs, all metabolites were tested for
association with drug status/use using Kruskal-Wallistests. Those metabolites that were even nominally asso-
ciated with drug status (p < 0.05) were filtered out prior
to model building as they may potentially be related to
drug metabolism and/or response. While this may be
overly conservative, we wanted to be certain that any po-
tential discrimination gained by adding the metabolites
into a model was not confounded by drug response/me-
tabolism. Additionally, metabolites were tested for asso-
ciation with both the ApoE genotype, with genotype
coded as high risk and low risk groups (where E3/E4 an
E4/E4 genotypes were high risk and all others were con-
sidered low risk) using Kruskal-Wallis tests of associ-
ation. Again, nominally associated metabolites were
removed prior to model building to prevent confounding
with risk genotype.
Once the metabolites were filtered for independence
from drug use and genotype, forward step-wise logistic
regression was performed using a Bayesian Information
Criterion (BIC) for variable selection and modeling with
several different sets of variables. First, models were
built using each of the following types of variables alone
to evaluate the maximal potential prediction from each
set of variables: Luminex proteins, LC-ECA metabolites,
and GC-TOF metabolites. Second, model building was
performed using all possible two-way combinations of
variables (e.g., Luminex proteins plus the LC-ECA me-
tabolites, Luminex proteins plus the GC-TOF metabo-
lites, etc.). Next, models were built with all possible
three-way combinations of variables. Finally, modeling
was performed with all possible predictive variables.
In order to assess the predictive performance of the
metabolites (and to limit potential overfitting), the
model building was performed using five-fold cross-
validation to evaluate the stability of the variable selec-
tion and model fit. The step-wise modeling approach
was repeated for every 4/5 split of the data, and the vari-
ables included in the model were recorded along with a
training AUC and a testing AUC (calculated on the 1/5
of the data left out of model building). In each cross-
validation interval, the variables included were recorded,
as the final model was selected based on cross-validation
consistency (picking the variable[s] that were selected in
the most cross-validation models). By using cross-
validation, we were able to estimate a prediction error
from the withheld data used in the validation process.
While such an analysis is not as powerful for assessing
the true predictive performance of a model, it is well
established that k-fold cross-validation provides an
estimate of the predictive performance, and k = 5 is con-
sidered a reasonable compromise between bias and vari-
ance for this estimate [45-47].
The predictive performance of the resulting models
was evaluated using area-under the curve (AUC) values.
Because of the high dimensional and sparse nature of
Table 1 Participant demographics and clinical
characteristics
Characteristics AD CN p-value Test
(N = 40) (N = 38)
Mean Age +/- SD 69.0 +/- 9.1 69.5 +/- 9.7 0.825 T
Mean Years of
Education +/- SD
14.8 +/- 3.6 16.6 +/- 3.0 0.015 T
Mean MMSE +/- SD 19.9 +/- 7.7 29.2 +/- 1.3 1.0E-9 T
% Male 25.0 34.21 0.459 F
% Caucasian 82.5 86.8 1.00 F
% Taking Antidepressant 30.0 21.05 0.441 F
% Taking Antipsychotic 5.0 0.0 0.494 F
% Taking Anxioytic 12.5 13.2 1.00 F
% Taking Corticosteroids 2.5 13.2 0.104 F
% Taking Cholinesterase
Inhibitor
37.5 0.0 <1.0E-9 F
% Taking Memantine 15.0 0.0 0.026 F
% Taking Statins 20.0 26.3 0.595 F
Abbreviations: AD Alzheimer’s disease, CN Normal cognition, SD Standard
Deviation, T two-sample t test, two-sided, MMSE Mini-Mental State Exam
obtained at date closest to sample if not available concurrently, F Fisher’s
exact test, two-sided.
Table 2 Summary measures of model fit for each
resulting model for discriminating between AD vs.






X E 0.96 1.00* 0.90
X M 0.70 0.68 0.67
X P 0.92 0.97 0.83
X X P|E 0.90 0.93 0.89
X X P|M 0.89 0.88 0.88
X X X P|M|E 0.90* 0.92 0.89
These results are the average measures of model fit in the testing (not
training) sets across all cross validation intervals. The variables included in the
modeling process are highlighted in indicator columns, along with their
abbreviations. The data types are Luminex amyloid and tau-related proteins
(P), GC-TOF mass spectrometry metabolites (M) and LC-ECA metabolites (E).
Abbreviations: AD Alzheimer’s disease, AUC Area under the curve. *rounded.
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were better than would be expected by chance, we
performed permutation testing to ascribe statistical sig-
nificance to the resulting models. One thousand per-
muted datasets were generated, randomizing the case
status at the same proportions as in the real data, and
the entire data analysis procedure was repeated. The
best correlation coefficient and AUC for each permuted
dataset was recorded, and an empirical distribution of
model fit statistics was generated across the 1000 per-
muted datasets. Then the values from the real data ana-
lysis were compared to the empirical distribution to
generate an empirical p-value.
To test whether there were significant differences in
the predictive performances of the resulting models (i.e.,
whether the differences were just by chance or were
likely to represent true differences), DeLong’s tests were
performed between the different models. A Bonferroni
correction for the number of tests performed was used
to determine the alpha level for significance for these
AUC comparisons.
Finally, we used Pearson correlation analyses to test
for correlation of the best metabolites (from the final
predictive model) and MMSE scores.
Results
Demographic differences
Tests that compared clinical and demographic variables
showed the AD and control participants to be generally
well matched for age and gender. Among these variables,
the only significant differences between groups were a
higher educational level for controls (though this associ-
ation was only nominally significant) and the use of two
disease treatment drugs, cholinesterase inhibitor and/or
memantine, in a subset of AD participants (Table 1).
Drug associations
The results of the tests of association for the metabolites
against drug use resulted in 134 that were nominally as-
sociated. Additionally, two metabolites were nominally
associated with ApoE genotype status. Metabolites’ asso-
ciations and their p-values from the drug association
analysis are listed in Additional file 2. A list of the asso-
ciation results for each metabolite and ApoE genotype
status are listed in Additional file 3. These metabolites
were removed from the list of potential predictors for
the next stage of analysis, leaving a total of 238 metabo-
lites evaluated in the model building step.
Model building
The summary of the model fits from the stepwise logistic
regression modeling for the AD vs. control is listed in
Table 2. The final models are listed in Additional file 4,
with the logistic regression equation (with parameterestimates and included variables listed) for each cross-
validation interval. All models were statistically signifi-
cant according to the results of the permutation testing
(p < 0.05 in all cases). The results of the Delong’s test
comparisons of the discrimination of the models are
shown in Table 3, including the results for all two-way
combinations of resulting models. Only the statistically
significant p-values (using a Bonferroni correction) are
listed.
As expected, the model built with CSF Aβ, t-tau and
p-tau levels as measured in Luminex immunoasssays
showed good discrimination of AD versus controls with
Table 3 Results from the comparisons of prediction
models built on Luminex phosphorylated proteins (P),





E M P P|E P|M P|M|E
E —— —— —— —— ——
M 0.005 —— —— —— ——
P 0.004 —— —— ——
P|E 0.005 —— ——
P|M .045 0.005 ——
P|M|E 0.004
Abbreviations: AD Alzheimer’s disease, AUC Area under the curve.
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the LC-ECA metabolites was also highly discriminatory
with an average testing AUC of 0.96, slightly higher than
the model built with the Luminex proteins. Remarkably,
this discrimination was achieved with two metabolites that
consistently were included in each cross-validation inter-
val (5/5 cross-validation consistency): 15-65.533 and 8-93
.65 the identities of which are currently unknown. By
comparison, the GC-TOF mass spectrometry metabolites
resulted in a model with much lower predictive perform-
ance (average testing AUC of 0.70) than the LC-ECA me-
tabolites or Luminex proteins. Combining metabolomics
with pathology markers did not increase accuracy much
more and in some combinations reduced accuracy. To
visually discriminate the predictive power of the models,
the average performance (sensitivity and specificity) for
each resulting model is depicted in Additional file 5:
Figure S1. In this figure, better performance is seen as
a lift in the models to the upper left quadrant of the
graph. The models have been colored according toFigure 1 Box-plot distributions of metabolites 15-65.533 and 8-93.65
concentrations. The boxplots show the median and quartiles of each dist
values more than 1.5 times the interquartile range from the median.whether they used the metabolite variables in the
model (red) or did not (blue).
Since metabolites 15-65.533 and 8-93.65 had the most
consistent association, we show in Figure 1 the distribu-
tion values of these metabolites for AD and control par-
ticipants. It can be clearly seen that both of them are
elevated in AD. Our correlation analysis indicated that
there was only weak correlation between these metabo-
lites and the MMSE score (not statistically significant).
Discussion
These results show that in analyzing CSF, mapping the
concentrations of small molecules in the LC-ECA plat-
form produces initial prediction levels similar to those
produced by well validated CSF neuropathology-related
protein biomarkers for discriminating between clinically
diagnosed AD and cognitively normal participants. Fur-
ther, our data suggests that metabolomics markers alone
may offer relatively high discriminatory ability to distin-
guish the clinical AD phenotype from controls, and the
lack of correlation with MMSE suggests the markers
may have potential applicability also in mild stages
where there is relatively high need for accurate markers.
The current sample size is limited in its ability to truly
build and evaluate potential predictive models without
further evaluation and validation in larger studies; how-
ever, it is interesting that a model from a predictive
resampling scheme with only 2 metabolites could be
built that has high predictive potential. These results
were found with a conservative screening approach that
removed metabolites that are potential confounders due
to differential drug response and also ApoE status.
While the potential predictive performance of the 15-
65.533 and 8-93.65 metabolites is promising, their un-
known identity makes biological interpretation difficult.
This limits current interpretability, but it does demonstratefor Alzheimer’s disease (AD) participants and controls, in relative
ribution, with outliers marked with dots. Outliers were defined as
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identify novel metabolite markers that may be of biological
and clinical relevance. Studies are in progress to further
characterize and identify them, from both a bioinformatics
perspective and a biochemical perspective. This will be
helpful in enhancing our understanding of pathophysio-
logic mechanisms and the interrelationships between small
molecules and AD-associated proteins.
Initial analyses to explore correlations with 15-65.533
and 8-93.65 show that they are significantly associated
with several known metabolites that may help reveal
their biological relevance (Additional file 6: Table S1).
The correlation structure and pathway analyses of the
electrochemistry metabolites collected in the current
data are thoroughly discussed in a previous manuscript
[35]. Correlations of the two unknowns with other me-
tabolites in the study were tested in a post-hoc analysis
to try to interpret the potential biological relevance of
the unknown metabolite (with all metabolites, including
those that were associated with drug response). For ex-
ample, 15-65.533 is highly correlated with methionine
(P = 1E-6), which is also correlated with disease status.
Additionally, 15-65.533 is also correlated with several
other known metabolites, including Indole-3-propionic
acid (I-3-PA), Kynurenine (KYN), Indole-3-Acetic Acid
and Guanosine. While the mechanisms and potential
pathway relationships need to be evaluated in future
studies, there is previous evidence of the involvement of
these known metabolites in disease etiology. For ex-
ample, I-3-PA has been shown to be involved in neur-
onal damage and oxidative stress in the brain [48,49],
KYN is a major route of tryptophan metabolism and has
been implicated in pathogenesis of several neuropsychi-
atric diseases. Several metabolites within this pathway
were involved in the pathogenesis of AD in previous
studies [50,51]. The other unknown metabolite, 8-93.65,
is strongly correlated with MET (P = 3E-12) and gluta-
thione (GSH, P = 3E-5), both of which are elevated in
AD [35]. MET is the precursor for homocysteine and
cysteine, which plays a critical role in GSH synthesis.
The potential link of this pathway with AD along with
details of the data analysis has been discussed in our
previous manuscript [35].
In addition to the disease-metabolite associations, we
also identified drug-associated metabolites. While not the
primary goal of the current study, these associations may
reveal interesting biology of drug metabolism and/or re-
sponse. Again, as with the disease-associated metabolites,
the majority of the drug-associated metabolites are com-
pounds of unknown structure. Interestingly, one of the
known metabolites, I-3-PA, which was associated with
drug use, was associated with 15-65.533, potentially indi-
cating/reinforcing a shared mechanism between the drug
targets and disease etiology. This supports the potential ofthe metabolites to identify potential new drug targets by
revealing insights into disease susceptibility.
We also identified two metabolites that were associ-
ated with ApoE genotype;
Phosphoethanolamine is an ethanolamine derivative
that is used for synthesis of sphingomyelins that we pre-
viously implicated in AD [25], and monopalmitin (gly-
cerol 1-palmitate) a lipid implicated in membrane
integrity and stability and an energy storage source.
Should our findings be replicated and validated in a
larger study of pathologically confirmed AD, it may lead
to a clinically useful test. Similar studies in patients with
MCI are underway to determine whether these com-
bined models are capable of identifying distinct sub-
groups of MCI patients. Longitudinal follow-up of MCI
patients can then determine whether the “AD-like” bio-
marker profile predicts the progression of cognitive de-
cline and thus identifies a subgroup at high risk for
developing dementia. Such participant groups are likely
candidates for clinical trials of agents for slowing the
progression of cognitive decline. In addition, these stud-
ies will also need to be extended to patients with other
types of dementias, such as frontal temporal lobar de-
mentia, Parkinson’s disease dementia and Lewy body de-
mentias, to assess the specificity of these metabolites to
pathologic AD vs. other dementias.
In addition to the above-stated limitations of sample
size and current interpretability of results with metabo-
lites of unknown structure, our AD participants were
clinically diagnosed and we therefore did not have aut-
opsy confirmation as a gold standard. Since our object-
ive was to compare the performance of metabolomics
markers against standard CSF Ab42 and tau measures,
we did not use these measures to define pathologic AD.
Therefore, it is likely that about 20% of our AD partici-
pants did not meet criteria for pathologic AD and about
20% of controls might harbor preclinical disease, which
perhaps explains the observed accuracy of standard
Ab42 and tau markers.
Additionally, the lack of correlation between the metab-
olites selected in the prediction models and MMSE high-
lights the potential of these metabolites as predictors of
overall clinical AD diagnosis, and not necessarily a specific
stage. Given our sample included both mild and moderate
severity patients, studies of just mildly impaired patients
would be more informative of the utility of the markers
for early AD. Future studies should investigate these com-
plex relationships, and interrogate potential associations
amongst metabolites and other clinical and biological me-
diators and contributors to mild stages of AD.
Conclusion
In conclusion, our preliminary results suggest that in
analyzing CSF, some metabolomics variables have a high
Motsinger-Reif et al. Acta Neuropathologica Communications 2013, 1:28 Page 8 of 9
http://www.actaneurocomms.org/content/1/1/28discriminatory ability to distinguish patients with clinical
AD from cognitively normal controls. Further, our re-
sults show the potential of metabolite variables to pro-
vide discrimination potential of the same magnitude as
the CSF amyloid and tau proteins.
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